Blueprint appoints Charles Rowland to board
This article was originally published in Scrip
Blueprint Medicines, a company developing kinase drugs to treat patients with genomically defined diseases, has named Charles A Rowland Jr to its board of directors. Mr Rowland most recently served as vice-president and chief financial officer of ViroPharma, a global biopharmaceutical company. Before joining ViroPharma in 2008, Mr Rowland was executive vice-president and CFO, as well as interim co-CEO, for Endo Pharmaceuticals.